Neukam K, et al. - The current rates of seroconversion after receiving hepatitis A virus vaccine (HAV-V) in HIV-infected patients were determined under real-life conditions. Among 522 patients included, 343 received 2 doses (standard scheme) HAV-V from April 2008 to May 2016 and 179 received 1 single dose of HAV-V from June 2016 to February 2018 due to an HAV outbreak with shortage of HAV-V. Seroconversion was observed in 303/343 patients (88.3%) and 149/179 (83.2%) patients in the standard-dose group and the single-dose group, respectively. Findings emphasize encouraging HIV-infected patients to undergo HAV-V with 2 standard doses 6 months apart. Patients with favorable response factors show a high rate of seroconversion on receiving a single dose. Hence, future outbreaks could be limited by providing a single dose sufficiently in case of HAV-V shortage until supply is reestablished.